761 results on '"Warnke, Clemens"'
Search Results
2. Six-month follow-up of multidomain cognitive impairment in non-hospitalized individuals with post-COVID-19 syndrome
3. Correction to: Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management
4. Persons with multiple sclerosis older than 55 years: an analysis from the German MS registry
5. “So at least now I know how to deal with things myself, what I can do if it gets really bad again”—experiences with a long-term cross-sectoral advocacy care and case management for severe multiple sclerosis: a qualitative study
6. Cognitive decline in post-COVID-19 syndrome does not correspond with persisting neuronal or astrocytic damage
7. Cerebrospinal fluid findings in patients with neurological manifestations in post-COVID-19 syndrome
8. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management
9. Absence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum
10. Entzündliche und erregerbedingte Erkrankungen
11. Multidomain cognitive impairment in non-hospitalized patients with the post-COVID-19 syndrome: results from a prospective monocentric cohort
12. Association of health behaviour and clinical manifestation in early multiple sclerosis in Germany – Baseline characteristics of the POWER@MS1 randomised controlled trial
13. Analysis of Cerebral CT Based on Supervised Machine Learning as a Predictor of Outcome After Out-of-Hospital Cardiac Arrest
14. Fitness, physical activity, and exercise in multiple sclerosis: a systematic review on current evidence for interactions with disease activity and progression
15. Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysis
16. Innovative therapeutic concepts of progressive multifocal leukoencephalopathy
17. Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry
18. Absolute serum neurofilament light chain levels and its early kinetics predict brain injury after out-of-hospital cardiac arrest
19. Directly Isolated Allogeneic Virus–Specific T Cells in Progressive Multifocal Leukoencephalopathy.
20. Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity
21. Hemiparese bei Klappenvegetationen und Panzytopenie
22. Der kritisch kranke Patient nach CAR-T-Zell-Therapie: Relevante Nebenwirkungen, deren Management und Herausforderungen an die Intensivmedizin
23. Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology
24. Autorenverzeichnis
25. Sequenzen verlaufsmodifizierender Therapie
26. Toxizitäten nach Chimärer-Antigenrezeptor-T-Zell-Therapie: Übersicht und Management früher und verzögerter Nebenwirkungen
27. Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry
28. A systematic review of neurological symptoms and complications of COVID-19
29. Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry
30. Successful treatment of thromboses of major arteries after ChAdOx1 nCov-19 vaccination
31. Diagnostik und Therapie von Tuberkulose unter Immuntherapien für Multiple Sklerose: Aktueller Stand und Empfehlungen in Deutschland
32. JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants.
33. Disease-modifying therapy initiation patterns in multiple sclerosis in three large MS populations.
34. Häufiger als gedacht – ein Update zu Dysphagie bei Multipler Sklerose.
35. Cerebrospinal fluid findings in patients with neurological manifestations in post-COVID-19 syndrome
36. Association of health behaviour and clinical manifestation in early multiple sclerosis in Germany – Baseline characteristics of the POWER@MS1 randomised controlled trial
37. Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
38. Progressive Multifocal Leukoencephalopathy
39. Managing Risks with Immune Therapies in Multiple Sclerosis
40. The Extracellular Domains of FasL and Fas Are Sufficient for the Formation of Supramolecular FasL-Fas Clusters of High Stability
41. Physical activity is related to disease severity and fatigue, but not to relapse rate in persons with relapsing remitting multiple sclerosis – a self-reported questionnaire based study
42. Adoptive Allogeneic T-Cell Therapy Improves the Clinical Outcome of JC Virus Granule Cell Neuronopathy
43. Subjective and Objective Cognitive Deficits in Patients with Post-COVID Syndrome
44. Cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy
45. Cultural adaptation of the Integrated Palliative care Outcome Scale for neurological symptoms.
46. Ocrelizumab initiation in patients with MS: A multicenter observational study
47. Natalizumab-associated progressive multifocal leukoencephalopathy in Germany
48. Real-world data on eculizumab treatment in NMOSD: high efficacy and potential challenges (P13-5.017)
49. Association of cerebrospinal fluid brain-binding autoantibodies with cognitive impairment in post-COVID-19 syndrome
50. Erratum zu: Toxizitäten nach Chimärer-Antigenrezeptor-T-Zell-Therapie
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.